A reversion of an IL2RG mutation in combined immunodeficiency providing competitive advantage to the majority of CD8+ T cells

Haematologica

Volumn 98, Issue 7, 2013, Pages 1030-1038

  Kuijpers, Taco W ^b   van Leeuwen, Ester M M ^c   Barendregt, Barbara H ^d   Klarenbeek, Paul ^c   aan de Kerk, Daan J ^c   Baars, Paul A ^c   Jansen, Machiel H ^c   de Vries, Niek ^c   van Lier, René A W ^a,c   Van Der Burg, Mirjam ^d  

^a CENTRAL LABORATORY   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; COTRIMOXAZOLE; CYTOKINE; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA;

ACRODERMATITIS; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHILD; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE; GENE MUTATION; GENOTYPE; HISTOGRAM; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IL2RG GENE; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE TEST; MALE; MOLLUSCUM CONTAGIOSUM; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; PRESCHOOL CHILD; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; X CHROMOSOME;

CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHILD; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LYMPHOCYTE COUNT; MALE; MUTATION; PEDIGREE; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 84879587505     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.077511     Document Type: Article

References (48)

1. Youssoufian H, Pyeritz RE. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet. 2002;3(10):748-58.
2. Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. J Med Genet. 2003;40(10):721-8.
3. Gregory JJ Jr, Wagner JE, Verlander PC, Levran O, Batish SD, Eide CR, et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci USA. 2001;98(5):2532-7.
4. Wada T, Schurman SH, Otsu M, Garabedian EK, Ochs HD, Nelson DL, Candotti F. Somatic mosaicism in Wiskott- Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci USA. 2001;98(15):8697-702.
5. Uzel G, Tng E, Rosenzweig SD, Hsu AP, Shaw JM, Horwitz ME, Linton GF, et al. Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1). Blood. 2008;111(1):209-18.
6. Pasmooij AM, Pas HH, Deviaene FC, Nijenhuis M, Jonkman MF. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am J Hum Genet. 2005;77(5):727-40.
7. Cavazzana-Calvo M, Hacein-Bey-Abina S, Fischer A. Gene therapy of X-linked severe combined immunodeficiency. Curr Opin Allergy Clin Immunol. 2002;2(6):507-9.
8. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-58.
9. Buckley RH. The multiple causes of human SCID. J Clin Invest. 2004;114(10):1409-11.
10. Hirschhorn R, Israni A, Yang DR, Israni A, Huie ML, Ownby DR. Somatic mosaicism for a newly identified splice site mutation in a patient with adenosine deaminase deficient immunodeficency (ADA-SCID) and spontaneous clinical recovery. Am J Hum Genet. 1994;55(1):59-68.
11. Hirschhorn R, Yang DR, Puck JM, Huie ML, Jiang CK, Kurlandsky LE. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet. 1996;13(3):290-5.
12. Ariga T, Oda N, Yamaguchi K, Kawamura N, Kikuta H, Taniuchi S, et al. T cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood. 2001;97 (9):2896-9.
13. Arredondo-Vega FX, Santisteban I, Richard E, Bali P, Koleilat M, Loubser M, et al. Adenosine deaminase deficiency with mosaicism for a 'second-site suppressor' of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. Blood. 2002;99(3):1005-13.
14. Moncada-Vélez M, Vélez-Ortega A, Orrego J, Santisteban I, Jagadeesh J, Olivares M, et al. Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype. Scand J Immunol. 2011;74(5):471-81.
15. Davis BR, Yan Q, Bui JH, Felix K, Moratto D, Muul LM, et al. Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants. Clin Immunol. 2010;135(1): 72-83.
16. Wada T, Konno A, Schurman SH, Garabedian EK, Anderson SM, Kirby M, et al. Second-site mutation in the Wiskott- Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings. J Clin Invest. 2003;111(9):1389-97.
17. Lutskiy MI, Beardsley DS, Rosen FS, Remold-O'Donnell E. Mosaicism of NK cells in a patient with Wiskott-Aldrich syndrome. Blood. 2005;106(8):2815-7.
18. Rieux-Laucat F, Hivroz C, Lim A, Mateo V, Pellier I, Selz F, et al. Inherited and somatic CD3zeta mutations in a patient with T-cell deficiency. N Engl J Med. 2006;354(18): 1913-21.
19. Wada T, Toma T, Okamoto H, Kasahara Y, Koizumi S, Agematsu K, et al. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency. Blood. 2005;106(6):2099-101.
20. Tone Y, Wada T, Shibata F, Toma T, Hashida Y, Kasahara Y, et al. Somatic revertant mosaicism in a patient with leukocyte adhesion deficiency type 1. Blood. 2007; 109(3):1182-4.
21. Nishikomori R, Akutagawa H, Maruyama K, Nakata-Hizume M, Ohmori K, Mizuno K, et al. X-linked ectodermal dysplasia and immunodeficiency caused by reversion mosaicism of NEMO reveals a critical role for NEMO in human T-cell development and/or survival. Blood. 2004;103(12):4565-72.
22. Conley ME. Molecular approaches to analysis of X-linked immunodeficiencies. Annu Rev Immunol. 1992;10:215-38.
23. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, et al. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73(1):147-57.
24. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009;9(7):480-90.
25. Stephan V, Wahn V, Le Deist F, Dirksen U, Broker B, Müller-Fleckenstein I, et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med. 1996;335(21):1563-7.
26. Speckmann C, Pannicke U, Wiech E, Schwarz K, Fisch P, Friedrich W, et al. Clinical and immunologic consequences of a somatic reversion in a patient with Xlinked severe combined immunodeficiency. Blood. 2008;112(10):4090-7.
27. Wada T, Yasui M, Toma T, Nakayama Y, Nishida M, Shimizu M, et al. Detection of T lymphocytes with a second-site mutation in skin lesions of atypical X-linked severe combined immunodeficiency mimicking Omenn syndrome. Blood. 2008;112 (5):1872-5.
28. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev. 2005;203:127-42.
29. Brooks EG, Schmalstieg FC, Wirt DP, Rosenblatt HM, Adkins LT, Lookingbill DP, et al. A novel X-linked combined immunodeficiency disease. J Clin Invest. 1990; 86(5):1623-31.
30. Saint-Basile G, Le Deist F, Caniglia M, Lebranchu Y, Griscelli C, Fischer A. Genetic study of a new X-linked recessive immunodeficiency syndrome. J Clin Invest. 1992;89(3):861-6.
31. DiSanto JP, Rieux-Laucat F, Dautry-Varsat A, Fischer A, de Saint-Basile G. Defective human interleukin 2 receptor gamma chain in an atypical X chromosome-linked severe combined immunodeficiency with peripheral T cells. Proc Natl Acad Sci USA. 1994;91(20):9466-70.
32. Morelon E, Dautry-Varsat A, Le Deist F, Hacein-Bay S, Fischer A, de Saint-Basile G. T-lymphocyte differentiation and proliferation in the absence of the cytoplasmic tail of the common cytokine receptor gamma c chain in a severe combined immune deficiency X1 patient. Blood. 1996;88(5):1708-17.
33. Sharfe N, Shahar M, Roifman CM. An interleukin-2 receptor gamma chain mutation with normal thymus morphology. J Clin Invest. 1997;100(12):3036-43.
34. Kuijpers TW, Baars PA, Aan de Kerk DJ, Jansen MH, Derks IA, Bredius RG, et al. A novel mutation in CD132 causes X-CID with defective T-cell activation and impaired humoral reactivity. J Allergy Clin Immunol. 2011;128(6):1360-3.
35. Tone Y, Wada T, Shibata F, Toma T, Hashida Y, Kasahara Y, et al. Somatic revertant mosaicism in a patient with leukocyte adhesion deficiency type 1. Blood. 2007;109(3):1182-4.
36. Demers SI, Russo P, Lettre F, Tanguay RM. Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia. Hum Pathol. 2003;34(12):1313-20.
37. Choate KA, Lu Y, Zhou J, Choi M, Elias PM, Farhi A, et al. Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10. Science. 2010;330(6000):94-7.
38. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, et al. CD20 deficiency in humans results in impaired T cellindependent antibody responses. J Clin Invest. 2010;120(1):214-22.
39. van der Burg M, Kreyenberg H, Willasch A, Barendregt BH, Preuner S, Watzinger F, et al. Standardization of DNA isolation from low cell numbers for chimerism analysis by PCR of short tandem repeats. Leukemia. 2011;25(9):1467-70.
40. van der Burg M, Weemaes CM, Preijers F, Brons P, Barendregt BH, van Tol MJ, et al. Bcell recovery after stem cell transplantation of Artemis-deficient SCID requires elimination of autologous bone marrow precursor- B-cells. Haematologica. 2006;91(12):1705-9.
41. Klarenbeek PL, Tak PP, van Schaik BD, Zwinderman AH, Jakobs ME, Zhang Z, et al. Human T-cell memory consists mainly of unexpanded clones. Immunol Lett. 2010;133(1):42-8.
42. van Gisbergen KP, Klarenbeek PL, Kragten NA, Unger PP, Nieuwenhuis MB, Wensveen FM, et al. The costimulatory molecule CD27 maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral variants. Immunity. 2011;35(1):97-108.
43. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17(12):2257-317.
44. Folch G, Lefranc MP. The human T cell beta variable (TRBV) genes. Exp Clin Immunogenet. 2000;17(1):42-54.
45. Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol. 2009;27:29-60.
46. Bousso P, Wahn V, Douagi I, Horneff G, Pannetier C, Le Deist F, et al. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc Natl Acad Sci USA. 2000;97(1):274-8.
47. Palendira U, Low C, Bell AI, Ma CS, Abbott RJ, Phan TG, et al. Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein- Barr virus. J Exp Med. 2012;209(5): 913-24.
48. Park JH, Adoro S, Guinter T, Erman B, Alag AS, Catalfamo M, et al. Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxiclineage T cells. Nat Immunol. 2010;11(3): 257-64.